Drug wholesaler beginning to look at acquisitions in peri-approval services, including contract sales organizations, to add to its "homegrown" Marketforce. Senior VP-Business Development Timothy Wright told the Oct. 1 Pharmaceutical Strategic Alliances Conference in New York City that Cardinal began its move into contract sales last year because distribution customers "were coming to Cardinal, looking for new services" beyond Cardinal's existing pre-launch activities. Wright maintains that a principle running through "acquisitions that we have always followed is that we don't want to be competing with our potential customers"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth